Literature DB >> 20628831

Quality of life parameters, weight change and improvement of co-morbidities after laparoscopic Roux Y gastric bypass and laparoscopic gastric sleeve resection--comparative study.

Elemér Mohos1, Elizabeth Schmaldienst, Manfred Prager.   

Abstract

The laparoscopic Roux Y gastric bypass (LRYGB) and the laparoscopic gastric sleeve resection are frequently used methods for the treatment of morbid obesity. Quality of life, weight loss and improvement of the co-morbidities were examined. Match pair analysis of the prospectively collected database of the 47 gastric bypass and 47 gastric sleeve resection patients operated on in our hospital was performed. The quality of life parameters were measured with two standard questionnaires (SF 36 and Moorehead-Ardelt II). The mean preoperative and postoperative BMI was in gastric bypass group 46.1 and 28.1 kg/m(2) (mean follow-up: 15.7 months) and in gastric sleeve group 50.3 and 33.5 kg/m(2) (mean follow-up: 38.3 months). The SF 36 questionnaire yielded a mean total score of 671 for the bypass and 611 for the sleeve resection patients (p = 0.06). The Moorehead-Ardelt II test signed a total score of 2.09 for gastric bypass versus 1.70 for gastric sleeve patients (p = 0.13). Ninety percent of the diabetes was resolved in the bypass and 55% in the sleeve resection group. Seventy-three percent of the hypertension patients needed no more antihypertensive treatment after gastric bypass and 30% after sleeve resection. Ninety-two percent of the gastro-oesophageal reflux were resolved in the bypass group and 25% in the sleeve (with 33% progression) group. Ninety-four percent of the patients were satisfied with the result after gastric bypass and 90% after sleeve resection. The patients have scored a high level of satisfaction in both study groups. The gastric bypass is associated with a trend toward a better quality of life without reaching statistical significance, pronounced loss of weight and more remarkable positive effects on the co-morbidities comparing with the gastric sleeve resection.

Entities:  

Mesh:

Year:  2011        PMID: 20628831     DOI: 10.1007/s11695-010-0227-7

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  25 in total

1.  [The SF-36 in the Federal Health Survey--description of a current normal sample].

Authors:  U Ellert; B M Bellach
Journal:  Gesundheitswesen       Date:  1999-12

2.  Bands and bypasses: 30-day morbidity and mortality of bariatric surgical procedures as assessed by prospective, multi-center, risk-adjusted ACS-NSQIP data.

Authors:  Robert T Lancaster; Matthew M Hutter
Journal:  Surg Endosc       Date:  2008-09-20       Impact factor: 4.584

3.  Ten-year trends in health-related quality of life after surgical and conventional treatment for severe obesity: the SOS intervention study.

Authors:  J Karlsson; C Taft; A Rydén; L Sjöström; M Sullivan
Journal:  Int J Obes (Lond)       Date:  2007-03-13       Impact factor: 5.095

4.  Intraoperative endoscopic pneumatic testing for gastrojejunal anastomotic integrity during laparoscopic Roux-en-Y gastric bypass.

Authors:  M D Kligman
Journal:  Surg Endosc       Date:  2007-03-01       Impact factor: 4.584

Review 5.  [Type II diabetes. Permanent remission by surgery of the foregut].

Authors:  W Pories
Journal:  Chirurg       Date:  2009-05       Impact factor: 0.955

6.  The surgical treatment of type II diabetes mellitus: changes in HOMA Insulin resistance in the first year following laparoscopic Roux-en-Y gastric bypass (LRYGB) and laparoscopic adjustable gastric banding (LAGB).

Authors:  Garth H Ballantyne; Annette Wasielewski; John K Saunders
Journal:  Obes Surg       Date:  2009-07-23       Impact factor: 4.129

7.  Physical and psychosocial outcome in morbidly obese patients with and without bariatric surgery: a 4 1/2-year follow-up.

Authors:  Barbara Buddeberg-Fischer; Richard Klaghofer; Lucas Krug; Claus Buddeberg; Markus K Müller; Othmar Schoeb; Markus Weber
Journal:  Obes Surg       Date:  2006-03       Impact factor: 4.129

8.  Laparoscopic Roux-en-Y gastric bypass in morbidly obese patients > or =55 years old.

Authors:  Rafael Fazylov; Eliana Soto; Stephen Merola
Journal:  Obes Surg       Date:  2008-04-12       Impact factor: 4.129

9.  Does gastric dilatation limit the success of sleeve gastrectomy as a sole operation for morbid obesity?

Authors:  Felix B Langer; Arthur Bohdjalian; Franz X Felberbauer; Edith Fleischmann; Mir A Reza Hoda; Bernhard Ludvik; Johannes Zacherl; Raimund Jakesz; Gerhard Prager
Journal:  Obes Surg       Date:  2006-02       Impact factor: 4.129

10.  The validation of the Moorehead-Ardelt Quality of Life Questionnaire II.

Authors:  Melodie K Moorehead; Elisabeth Ardelt-Gattinger; Hans Lechner; Horacio E Oria
Journal:  Obes Surg       Date:  2003-10       Impact factor: 4.129

View more
  14 in total

1.  Quality of life, weight loss and improvement of co-morbidities after primary and revisional laparoscopic roux Y gastric bypass procedure-comparative match pair study.

Authors:  Elemer Mohos; Zoltán Jánó; Doris Richter; Elizabeth Schmaldienst; Gábor Sándor; Petra Mohos; Miroslav Horzov; Gábor Tornai; Manfred Prager
Journal:  Obes Surg       Date:  2014-12       Impact factor: 4.129

2.  Remission of Type 2 Diabetes and Sleeve Gastrectomy in Morbid Obesity: a Comparative Systematic Review and Meta-analysis.

Authors:  Ferdous Madadi; Rami Jawad; Ismail Mousati; Philip Plaeke; Guy Hubens
Journal:  Obes Surg       Date:  2019-12       Impact factor: 4.129

3.  Relationship Between Bariatric Surgery and Gastroesophageal Reflux Disease: a Systematic Review and Meta-analysis.

Authors:  Lihu Gu; Bangsheng Chen; Nannan Du; Rongrong Fu; Xiaojing Huang; Feiyan Mao; Parikshit Asutosh Khadaroo; Shenbiao Zhao
Journal:  Obes Surg       Date:  2019-12       Impact factor: 4.129

4.  How Far Can Our Expectations Go on Revisional Bariatric Surgery After Failed Adjustable Gastric Banding?

Authors:  André Pereira; André Costa Pinho; Hugo Santos Sousa; Eduardo Lima da Costa; Sara Rodrigues; Elisabete Barbosa; John Preto
Journal:  Obes Surg       Date:  2021-01-12       Impact factor: 4.129

Review 5.  Excessive weight loss after sleeve gastrectomy: a systematic review.

Authors:  Lars Fischer; Caroline Hildebrandt; Thomas Bruckner; Hannes Kenngott; Georg R Linke; Tobias Gehrig; Markus W Büchler; Beat P Müller-Stich
Journal:  Obes Surg       Date:  2012-05       Impact factor: 4.129

6.  Laparoscopic sleeve gastrectomy versus laparoscopic Roux-en-Y gastric bypass for morbid obesity and related comorbidities: a meta-analysis of 21 studies.

Authors:  Yong Zhang; Ju Wang; Wang Ju; Xiangyu Sun; Zhangou Cao; Zhanguo Cao; Xinsheng Xu; Xu Xinsheng; Daquan Liu; Liu Daquan; Xiangyang Xin; Xin Xiangyang; Mingfang Qin
Journal:  Obes Surg       Date:  2015-01       Impact factor: 4.129

7.  The effect of bariatric surgery on patient HRQOL and sexual health during a 1-year postoperative period.

Authors:  Vasileios Efthymiou; Thomas Hyphantis; Katerina Karaivazoglou; Philippos Gourzis; Theodoros K Alexandrides; Fotios Kalfarentzos; Konstantinos Assimakopoulos
Journal:  Obes Surg       Date:  2015-02       Impact factor: 4.129

8.  A randomized clinical trial of laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy for the treatment of morbid obesity in China: a 5-year outcome.

Authors:  Yong Zhang; Hongzhi Zhao; Zhanguo Cao; Xiangyu Sun; Chen Zhang; Wang Cai; Rong Liu; Sanyuan Hu; Mingfang Qin
Journal:  Obes Surg       Date:  2014-10       Impact factor: 4.129

Review 9.  Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy to Treat Morbid Obesity-Related Comorbidities: a Systematic Review and Meta-analysis.

Authors:  Jianfang Li; Dandan Lai; Dongping Wu
Journal:  Obes Surg       Date:  2016-02       Impact factor: 4.129

10.  Patient-reported quality of life after bariatric surgery: a single institution analysis.

Authors:  Andrew J Vegel; Neil Shah; Anne O Lidor; Jacob A Greenberg; Ying Shan; Xing Wang; Luke M Funk
Journal:  J Surg Res       Date:  2017-06-15       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.